AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9215091 — intervention group
Group type: EXPERIMENTAL
Intervention: Valaciclovir (500 mg once daily)
Number of subjects: 382
Study 9215091 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 382
Study 8314294 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 g cefuroxime i.v. as a single bolus 20 minutes before surgical incision
Number of subjects: 66
Study 8314294 — intervention group
Group type: COMPARATOR
Intervention: 1.5 g cefuroxime i.v. injected 20 minutes after incision
Number of subjects: 66
Study 3685069 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg/kg diazepam
Number of subjects: 24
Study 3685069 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 31623493 — intervention group
Group type: COMPARATOR
Intervention: Pregabalin controlled-release (CR) 165 and 330 mg/day
Number of subjects: 323
Study 31623493 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 323
Study 28228410 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-piece IOL model
Number of subjects: 50
Study 28228410 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-piece IOL model
Number of subjects: 50
Study 28228410 — intervention group
Group type: COMPARATOR
Intervention: Preoperative parameters (axial length, anterior chamber depth)
Number of subjects: 50
Study 28228410 — intervention group
Group type: COMPARATOR
Intervention: Regression analysis
Number of subjects: 50
Study 26626148 — intervention group
Group type: COMPARATOR
Intervention: Low-dose GTP (500 mg)
Number of subjects: 124
Study 26626148 — intervention group
Group type: COMPARATOR
Intervention: High-dose GTP (1,000 mg)
Number of subjects: 124
Study 26626148 — intervention group
Group type: COMPARATOR
Intervention: GTP treatment (both doses)
Number of subjects: 124
Study 26626148 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 124
Study 23300343 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical mitomycin C (MMC) 40 mg within 6 hours after TURBT
Number of subjects: 49
Study 23300343 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary alkalinization prior to MMC
Number of subjects: 49
Study 23300343 — intervention group
Group type: COMPARATOR
Intervention: No drug treatment (control group)
Number of subjects: 49
Study 23300343 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard group vs Optimized group
Number of subjects: 49
Study 23300343 — intervention group
Group type: COMPARATOR
Intervention: Control group vs Optimized group
Number of subjects: 49
Study 23300343 — intervention group
Group type: COMPARATOR
Intervention: Control group vs Standard group
Number of subjects: 49
Study 21563963 — intervention group
Group type: EXPERIMENTAL
Intervention: Phytothermotherapy for 10 days
Number of subjects: 218
Study 21563963 — intervention group
Group type: COMPARATOR
Intervention: Control group (regular outpatient care)
Number of subjects: 218
Study 18654069 — intervention group
Group type: EXPERIMENTAL
Intervention: guaifenesin/pseudoephedrine
Number of subjects: 601
Study 18654069 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 601
Study 16239607 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy cycle ergometer exercise under hypoxic conditions (3,810 m)
Number of subjects: 8
Study 16239607 — intervention group
Group type: COMPARATOR
Intervention: Normoxic exercise
Number of subjects: 8
Study 16239607 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy cycle ergometer exercise at altitude (3,810 m)
Number of subjects: 8
Study 14769323 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary closure with two interrupted sutures using 3‐0 chromic catgut (Group 1)
Number of subjects: 39
Study 14769323 — intervention group
Group type: COMPARATOR
Intervention: Secondary healing (Group 2)
Number of subjects: 39
Study 11580731 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal palpation test
Number of subjects: 20
Study 9212308 — intervention group
Group type: EXPERIMENTAL
Intervention: Human insulin (H)
Number of subjects: 20
Study 9212308 — intervention group
Group type: COMPARATOR
Intervention: Porcine insulin (P)
Number of subjects: 20
Study 9212308 — intervention group
Group type: EXPERIMENTAL
Intervention: Both insulins
Number of subjects: 20
Study 8484622 — intervention group
Group type: EXPERIMENTAL
Intervention: Max‐EPA (3.2 g/day eicosapentaenoic acid)
Number of subjects: 37
Study 8484622 — intervention group
Group type: COMPARATOR
Intervention: Placebo (olive oil)
Number of subjects: 37
Study 3554063 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamicel
Number of subjects: 219
Study 3554063 — intervention group
Group type: COMPARATOR
Intervention: Multiple laminaria
Number of subjects: 219
Study 29449506 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab (ADA) 40 mg subcutaneously every other week for 6 weeks
Number of subjects: 49
Study 29449506 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 29449506 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab (ADA)
Number of subjects: 49
Study 26910749 — intervention group
Group type: EXPERIMENTAL
Intervention: Progesterone supplementation following ART (dydrogesterone)
Number of subjects: 1140
Study 26910749 — intervention group
Group type: COMPARATOR
Intervention: No progesterone supplementation (control group)
Number of subjects: 1140
Study 26910749 — intervention group
Group type: EXPERIMENTAL
Intervention: Dydrogesterone only
Number of subjects: 1140
Study 26910749 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of dydrogesterone and hydroxyprogesterone caproate
Number of subjects: 1140
Study 24924427 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate pressure distribution models
Number of subjects: 0
Study 24924427 — intervention group
Group type: COMPARATOR
Intervention: Over-concentrated pressure distribution models
Number of subjects: 0
Study 24924427 — intervention group
Group type: COMPARATOR
Intervention: Over-even pressure distribution models
Number of subjects: 0
Study 22433581 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term (7 day) urethral catheterization
Number of subjects: 512
Study 22433581 — intervention group
Group type: COMPARATOR
Intervention: Longer-term (14 day) urethral catheterization
Number of subjects: 512
Study 21246845 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment based on syndrome differentiation, using Ashi points and specific acupuncture points (Yanglingquan, Taichong, Zusanli)
Number of subjects: 100
Study 21246845 — intervention group
Group type: COMPARATOR
Intervention: Muscular injection of Bucinnazine
Number of subjects: 100
Study 21246845 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 100
Study 21246845 — intervention group
Group type: COMPARATOR
Intervention: Medication (Bucinnazine)
Number of subjects: 100
Study 18441320 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel 600 mg > 6 h before CAG (group A)
Number of subjects: 1028
Study 18441320 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel 600 mg in the cath-lab after CAG only in case of PCI (group B)
Number of subjects: 1028
Study 11160558 — intervention group
Group type: EXPERIMENTAL
Intervention: Low fat, high carbohydrate diet (< or =24% fat)
Number of subjects: 0
Study 11160558 — intervention group
Group type: COMPARATOR
Intervention: Low fat diet
Number of subjects: 0
Study 11160558 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive reduction of dietary fat with isocaloric substitution of carbohydrate
Number of subjects: 0
Study 9734550 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (20 mg/day) for 50 weeks
Number of subjects: 395
Study 9734550 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (20 mg/day) for 38 weeks and then 12 weeks of placebo
Number of subjects: 395
Study 9734550 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (20 mg/day) for 14 weeks and then 36 weeks of placebo
Number of subjects: 395
Study 9734550 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 50 weeks
Number of subjects: 395
Study 7925206 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium 0.6 mg kg‐1
Number of subjects: 60
Study 7925206 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium 0.75 mg kg‐1
Number of subjects: 60
Study 7925206 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium 0.9 mg kg‐1
Number of subjects: 60
Study 7925206 — intervention group
Group type: COMPARATOR
Intervention: Intubation conditions assessed at 45 s
Number of subjects: 60
Study 7925206 — intervention group
Group type: COMPARATOR
Intervention: Intubation conditions assessed at 60 s
Number of subjects: 60
Study 3287909 — intervention group
Group type: EXPERIMENTAL
Intervention: Piroxicam 40 mg for two days
Number of subjects: 68
Study 3287909 — intervention group
Group type: EXPERIMENTAL
Intervention: Piroxicam 20 mg for five days
Number of subjects: 68
Study 3287909 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg four times per day
Number of subjects: 68
Study 3287909 — intervention group
Group type: EXPERIMENTAL
Intervention: Piroxicam 40 mg for one day
Number of subjects: 68
Study 3287909 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study 31380560 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron status (measured by various biomarkers)
Number of subjects: 0
Study 31380560 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron status (liberal approach)
Number of subjects: 0
Study 29188889 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin B12 intake (assessed in a subsample)
Number of subjects: 2919
Study 29188889 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin B12 intake
Number of subjects: 2919
Study 29188889 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin B12 levels
Number of subjects: 2919
Study 29188889 — intervention group
Group type: EXPERIMENTAL
Intervention: HoloTC levels
Number of subjects: 2919
Study 29188889 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin B12 and HoloTC levels
Number of subjects: 2919
Study 26180220 — intervention group
Group type: EXPERIMENTAL
Intervention: Videoconference educational outreach
Number of subjects: 0
Study 26180220 — intervention group
Group type: COMPARATOR
Intervention: In-person educational outreach
Number of subjects: 0
Study 26180220 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 0
Study 23446895 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma TFAs
Number of subjects: 305
Study 20822942 — intervention group
Group type: EXPERIMENTAL
Intervention: Real rTMS targeting the right secondary somatosensory cortex (SII) for 10 days
Number of subjects: 0
Study 20822942 — intervention group
Group type: EXPERIMENTAL
Intervention: Real rTMS targeting the right secondary somatosensory cortex (SII)
Number of subjects: 0
Study 20822942 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS (control group)
Number of subjects: 0
Study 18810233 — intervention group
Group type: EXPERIMENTAL
Intervention: Very Early Mobilisation (VEM)
Number of subjects: 71
Study 18810233 — intervention group
Group type: COMPARATOR
Intervention: Standard Care (SC)
Number of subjects: 71
Study 16571878 — intervention group
Group type: EXPERIMENTAL
Intervention: 90 microg subvirion influenza A (H5N1) vaccine
Number of subjects: 451
Study 16571878 — intervention group
Group type: EXPERIMENTAL
Intervention: 45 microg subvirion influenza A (H5N1) vaccine
Number of subjects: 451
Study 16571878 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 microg subvirion influenza A (H5N1) vaccine
Number of subjects: 451
Study 16571878 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5 microg subvirion influenza A (H5N1) vaccine
Number of subjects: 451
Study 16571878 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 451
Study 12752833 — intervention group
Group type: EXPERIMENTAL
Intervention: PENS plus PT
Number of subjects: 34
Study 12752833 — intervention group
Group type: COMPARATOR
Intervention: Sham PENS plus PT
Number of subjects: 34
Study 10681608 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcipotriol cream (50 microg/g) combined with twice weekly broad-band UVB
Number of subjects: 0
Study 9080870 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine (5 mg base/kg, n = 20)
Number of subjects: 91
Study 9080870 — intervention group
Group type: EXPERIMENTAL
Intervention: Primaquine (0.5 mg base/kg, n = 30)
Number of subjects: 91
Study 9080870 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 41)
Number of subjects: 91
Study 8442748 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behaviour Therapy
Number of subjects: 0
Study 8442748 — intervention group
Group type: EXPERIMENTAL
Intervention: Behaviour Therapy
Number of subjects: 0
Study 30783724 — intervention group
Group type: EXPERIMENTAL
Intervention: Joint tip graft
Number of subjects: 30
Study 30783724 — intervention group
Group type: COMPARATOR
Intervention: Joint tip graft not used (Control)
Number of subjects: 30
Study 29148904 — intervention group
Group type: EXPERIMENTAL
Intervention: Without watertight duraplasty (test group)
Number of subjects: 58
Study 29148904 — intervention group
Group type: COMPARATOR
Intervention: With watertight duraplasty (control group)
Number of subjects: 58
Study 26901534 — intervention group
Group type: EXPERIMENTAL
Intervention: AFO-ON
Number of subjects: 11
Study 26901534 — intervention group
Group type: COMPARATOR
Intervention: AFO-OFF
Number of subjects: 11
Study 25268505 — intervention group
Group type: EXPERIMENTAL
Intervention: Interval walking training (IWT)
Number of subjects: 28
Study 25268505 — intervention group
Group type: COMPARATOR
Intervention: Control (CNT)
Number of subjects: 28
Study 22333328 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (oral, Revia)
Number of subjects: 58
Study 22333328 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study 22333328 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% alcohol availability
Number of subjects: 58
Study 22333328 — intervention group
Group type: EXPERIMENTAL
Intervention: 80% alcohol availability
Number of subjects: 58
Study 22333328 — intervention group
Group type: EXPERIMENTAL
Intervention: Locked trials during 80% availability
Number of subjects: 58
Study 20738437 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate‐intensity or more‐vigorous physical activity (MVPA)
Number of subjects: 424
Study 18600342 — intervention group
Group type: EXPERIMENTAL
Intervention: Harmonic Scalpel Group (HS-G)
Number of subjects: 76
Study 18600342 — intervention group
Group type: COMPARATOR
Intervention: Clip-Ligation Group (CL-G)
Number of subjects: 76
Study 16928842 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin 250 mg tablets given twice daily
Number of subjects: 199
Study 16928842 — intervention group
Group type: COMPARATOR
Intervention: Clarithromycin 500 mg extended-release tablets given once daily
Number of subjects: 199
Study 14605279 — intervention group
Group type: EXPERIMENTAL
Intervention: HP-HF (high permeability haemofiltration)
Number of subjects: 28
Study 14605279 — intervention group
Group type: COMPARATOR
Intervention: C-HF (conventional haemofiltration)
Number of subjects: 28
Study 14605279 — intervention group
Group type: EXPERIMENTAL
Intervention: HP ultrafiltrates
Number of subjects: 28
Study 14605279 — intervention group
Group type: COMPARATOR
Intervention: C ultrafiltrates
Number of subjects: 28
Study 11008045 — intervention group
Group type: EXPERIMENTAL
Intervention: MemoryLens
Number of subjects: 50
Study 11008045 — intervention group
Group type: COMPARATOR
Intervention: AcrySof
Number of subjects: 50
Study 8708224 — intervention group
Group type: EXPERIMENTAL
Intervention: Positioning with the unaffected lung down
Number of subjects: 39
Study 8708224 — intervention group
Group type: COMPARATOR
Intervention: Positioning with the affected lung down
Number of subjects: 39
Study 8708224 — intervention group
Group type: COMPARATOR
Intervention: Semi-Fowler's position
Number of subjects: 39
Study 1432551 — intervention group
Group type: EXPERIMENTAL
Intervention: Acoustic stimulation test (n = 62)
Number of subjects: 121
Study 1432551 — intervention group
Group type: COMPARATOR
Intervention: Oxytocin challenge test only (n = 59)
Number of subjects: 121
Study 1432551 — intervention group
Group type: COMPARATOR
Intervention: Oxytocin challenge test (n = 121)
Number of subjects: 121
Study 4064917 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 300 mg
Number of subjects: 9
Study 4064917 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 600 mg
Number of subjects: 9
Study 4064917 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 30807328 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding
Number of subjects: 120
Study 30807328 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Sucrose
Number of subjects: 120
Study 30807328 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 120
Study 29995062 — intervention group
Group type: EXPERIMENTAL
Intervention: Photobiomodulation (PBM)
Number of subjects: 51
Study 29995062 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual Therapy (MT)
Number of subjects: 51
Study 29995062 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined Therapy (CT)
Number of subjects: 51
Study 26874258 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine 40 μg.kg(‐1)
Number of subjects: 112
Study 26874258 — intervention group
Group type: COMPARATOR
Intervention: Neostigmine 0 μg.kg(‐1)
Number of subjects: 112
Study 26874258 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine 10 μg.kg(‐1)
Number of subjects: 112
Study 26874258 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine 20 μg.kg(‐1)
Number of subjects: 112
Study 24842862 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved unilateral recession-resection (R&R)
Number of subjects: 45
Study 24842862 — intervention group
Group type: COMPARATOR
Intervention: Unilateral medial rectus resection (UMR)
Number of subjects: 45
Study 24842862 — intervention group
Group type: COMPARATOR
Intervention: Bilateral medial rectus resections (BMR)
Number of subjects: 45
Study 24842862 — intervention group
Group type: EXPERIMENTAL
Intervention: All surgical procedures (UMR, BMR, R&R)
Number of subjects: 45
Study 22227912 — intervention group
Group type: EXPERIMENTAL
Intervention: Reusable SCLs
Number of subjects: 166
Study 22227912 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended Wear (EW) lenses
Number of subjects: 166
Study 22227912 — intervention group
Group type: EXPERIMENTAL
Intervention: Age (per year older)
Number of subjects: 166
Study 22227912 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone Hydrogel (SiHy)
Number of subjects: 166
Study 19342014 — intervention group
Group type: EXPERIMENTAL
Intervention: SonoAVC (automated measurement of follicle diameter)
Number of subjects: 72
Study 19342014 — intervention group
Group type: COMPARATOR
Intervention: 2D ultrasound (conventional measurement of follicle diameter)
Number of subjects: 72
Study 17427539 — intervention group
Group type: EXPERIMENTAL
Intervention: Ligation of intersphincteric fistula tract (LIFT) technique
Number of subjects: 18
Study 15766427 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized angle measurement software at a digital workstation
Number of subjects: 25
Study 15766427 — intervention group
Group type: COMPARATOR
Intervention: Standardized technique using a film marker and goniometer on plain film
Number of subjects: 25
Study 12063831 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of 5‐FU and radiation
Number of subjects: 0
Study 12063831 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine in chemoradiotherapy regimens
Number of subjects: 0
Study 12063831 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative therapy
Number of subjects: 0
Study 9627274 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalaprilat (0.5 mg bolus followed by incremental infusion up to 10 mg, mean 8.3 mg)
Number of subjects: 16
Study 9627274 — intervention group
Group type: COMPARATOR
Intervention: Control group (no enalaprilat)
Number of subjects: 16
Study 9627274 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalaprilat
Number of subjects: 16
Study 9627274 — intervention group
Group type: COMPARATOR
Intervention: Enalaprilat and Control
Number of subjects: 16
Study 8583442 — intervention group
Group type: EXPERIMENTAL
Intervention: Opsite skin closure
Number of subjects: 99
Study 8583442 — intervention group
Group type: COMPARATOR
Intervention: Subcuticular Vicryl
Number of subjects: 99
Study 2231061 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening for colorectal cancer; no specific intervention details provided.
Number of subjects: 0
Study 2231061 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening for prostate cancer; no specific intervention details provided.
Number of subjects: 0
Study 2231061 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening for skin cancer; no specific intervention details provided.
Number of subjects: 0
Study 2231061 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening for oral cancer; no specific intervention details provided.
Number of subjects: 0
Study 2231061 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening for testicular cancer; no specific intervention details provided.
Number of subjects: 0
Study 2231061 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical-examination cancer-screening procedure; no specific intervention details provided.
Number of subjects: 0
Study 2231061 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized screening trials funded by NCI; no specific intervention details provided.
Number of subjects: 0
Study 362197 — intervention group
Group type: EXPERIMENTAL
Intervention: 10‐mg clotrimazole buccal troches taken five times daily for two weeks
Number of subjects: 20
Study 362197 — intervention group
Group type: COMPARATOR
Intervention: Placebo taken five times daily for two weeks
Number of subjects: 20
Study 30958973 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine supplementation (0.1 g·kg‐1·day‐1 of creatine + 0.1 g·kg‐1·day‐1 of maltodextrin) during 8 weeks of HVRT
Number of subjects: 0
Study 30958973 — intervention group
Group type: EXPERIMENTAL
Intervention: High-velocity resistance training (HVRT)
Number of subjects: 0
Study 30958973 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.2 g·kg‐1·day‐1 of maltodextrin) during 8 weeks of HVRT
Number of subjects: 0
Study 28636579 — intervention group
Group type: EXPERIMENTAL
Intervention: Regeneration group
Number of subjects: 130
Study 28636579 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance group
Number of subjects: 130
Study 28636579 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 130